About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Systemic Diseases group performs translational research based on at least 300 patients with systemic lupus erytomatosus (SLE), antiphospholipid syndrome (APS), systemic sclerosis, vasculitis, dermatomyitis, Sjörgen syndrome or autoinflammatory syndromes in order to better understand their pathogenesis (both at the immunological and genetic regulation level), study their clinical and biological expression (through the detection of new markers that help characterize each of the autoimmune diseases), study morbimortality (through epidemiological studies) and analyse patients' response to medications. With these goals in mind, we seek to improve the diagnosis, clinical monitoring, and prognosis of our patients.
Cardiac involvement is one of the most important causes of dead in EGPE. The aim of this study is to investigate the prevalence of silent cardiac involvement in patients with EGPE, and if some chemotaxins (eotaxins 1, 2 and 3) may play a key role in its development, in order to establish an early tretament.
IP: Roser Solans Laque
IP: Jaume Alijotas Reig
Spanish multicenter clinical assay in collaboration with Vall d´Hebrón Hospital Haemophilia Unit and Spanish Society of Thrombosis and Haemostasis. The objective is to characterize the FVIII domains that act as epitopes for autoantibodies in acquired haemophilia, and its relationship with clinical manifestations and treatment of disease.
IP: José Pardos Gea
Subprograma de apoyo a proyectos singulares y estratégicos 2008-2009
IP: Sara Marsal Barril
PhD student: Andreu Fernández Codina, Andreu Fernández Codina, Andreu Fernández Codina, Andreu Fernández Codina Director/s: Inés de Torres Ramirez, Fernando Martínez Valle, Roser Solans Laque University: Universidad Autònoma de Barcelona Year: 2019
PhD student: Director/s: Javier Cortés Castan, Eva Muñoz Couselo, Vicente Peg Camara University: Universitat Autònoma de Barcelona Year: 2019
PhD student: Jaume Mestre Torres Director/s: Roser Solans Laque University: Universidad Autònoma de Barcelona Year: 2019
PhD student: Sara Nieves Maurel Ibáñez Director/s: José Alegre Martin University: Universidad Autònoma de Barcelona Year: 2018
15 researchers from the Rheumatology, Systemic Diseases and the Physiology and Pathophysiology of the Digestive Tract groups gave around 25 presentations.
The new technology allows more sensitive detection of scleroderma patients' autoantibodies, which are related to the severity and progression of the disease.
Researchers have used an innovative protocol to identify people with this autoimmune disease who have a higher risk of cancer.
